Company Active LTD

Company profile

17Cicada Ltd

Bot Verification

17Cicada Ltd is a UK company with status active founded in 2021 based in East of England.

CRN
13429166
Founded
2021
Age
5

Overview

Legal name
17CICADA LTD
Region
East of England
Registered address
ST. JOHN'S INNOVATION CENTRE
COWLEY ROAD
CAMBRIDGE
ENGLAND
CB4 0WS
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

5 events
31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

14 Sep
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Aug
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

31 May
2021

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2022
Funded years
2022, 2023
Age at first award
1 years

Projects

2023 Collaborative R&D Lead participant

Engineering a Microbial Platform for the Sustainable Production of Paclitaxel

1 Sep 2023 to 28 Feb 2025

Awarded
£240,286
Total cost £343,266

Paclitaxel (branded as Taxol) is one of the most important anticancer drugs and has been used for therapy of different types of cancer. It first gained FDA approval in 1992\. The compound, considered a blockbuster anticancer drug, was originally isolated from _Taxus brevifolia_ (Pacific yew), but is now known to be present in the approximately eleven _Tax...

2023 Collaborative R&D Lead participant

Sustainable, localised Farm-based microalgal fermentation to transform protein supplements for animal feedstock

1 Apr 2023 to 31 Mar 2025

Awarded
£184,164
Total cost £263,091

17Cicada anticipates the development of a revolutionary process that will allow individual farms to independently produce their own animal feed in a way that is sustainable, cost effective and with minimal environmental impact. 17Cicada aims to generate a robust and innovative way of utilising wastewater to support the growth of nutritional microalgae tha...

2022 Collaborative R&D Lead participant

Sustainable synthesis of Hyaluronic Acid via engineered strains of non-pathogenic bacteria - from carbon dioxide and waste feedstock to low-cost, sustainable, and waste-free Hyaluronic Acid for cosmetics, medicine, and nutraceuticals

1 Nov 2022 to 31 Oct 2024

Awarded
£248,142
Total cost £354,488

17Cicada anticipates market entry for its bacterial Hyaluronic Acid (HA) by 2025\. Our projected cumulative 5-year profits are of the order of £5.2 million (by 2029), i.e. 1033% return on investment (ROI) on project costs of £506,366 GBP. HA is widely distributed throughout connective, epithelial and neural tissues in human and animal bodies. It plays a s...

Product types

Collaborative R&D